Michael E. Wechsler, MD, MMSc
Professor of Medicine
Director, NJH Cohen Family Asthma Institute
Division of Pulmonary, Critical Care & Sleep Medicine
National Jewish Health
Emily DiMango, MD
Professor of Medicine
Director, John Edsall-John Wood Asthma Center
Columbia University Medical Center
New York, New York
.5 AMA PRA Category 1 Credit
.5 ABIM MOC points
Severe asthma affects only 3-6% of the overall population of asthmatics, but accounts for nearly half of the annual expenditures among asthma patients. Advances in the understanding of the pathophysiology of severe asthma have led to the identification of specific asthma endotypes and phenotypes that may be used to better tailor therapy in the future. This activity will explore the value of determining patient endotypes and phenotypes and review biomarker testing that can help clinicians appropriately classify severe asthma patients.
Pulmonologists, allergists, primary care physicians (PCPs), NPs, PAs and other healthcare providers who manage patients with severe asthma.
Upon completion of this educational activity, the participant should be able to:
- Identify the characteristics of uncontrolled, difficult-to-treat, and severe asthma.
- Describe how the pathophysiology of asthma produces distinct disease phenotypes/endotypes for characterization of severe asthma.
- Summarize clinical, laboratory, and other diagnostic findings that are consistent with each phenotype/endotype of severe asthma to improve treatment selection and asthma control.
Dr. Wechsler discloses the following:
Grants/Research Support: AstraZeneca, Teva, GlaxoSmithKline, Sanofi Genzyme Regeneron
Consultant: AstraZeneca, Teva, GlaxoSmithKline, Sanofi Genzyme Regeneron, Genetech/Novartis
Dr. DiMango discloses the following:
Advisory Board: AstraZeneca
The planners, managers, and other individuals, not previously disclosed, who are in a position to control the content of this continuing education activity hereby state that they have no relevant conflicts of interest and no financial relationships or relationships to products or devices during the past 12 months to disclose in relation to this activity. We are committed to providing participants with a quality learning experience and to improve clinical outcomes without promoting the financial interests of a proprietary business.
The credit providers require all faculty to disclose any planned discussion of an investigational and/or off-label use of a pharmaceutical product or device within their presentation. Participants should note that the use of products outside FDA-approved labeling should be considered experimental and are advised to consult current prescribing information for approved indications.
In this educational activity, the faculty reports that their presentation will not contain reference to investigational and/or off-label uses.
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the University of Cincinnati and MCM Education. The University of Cincinnati is accredited by the ACCME to provide continuing medical education for physicians.
Physician Credit Designation:
The University of Cincinnati designates this enduring material activity for a maximum of .50 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
American Board of Internal Medicine Maintenance of Certification (from ABIM):
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to .5 MOC points. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
The American Academy of Physician Assistants, the American Association of Nurse Practitioners and the American Nurses Credentialing Center accept certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by the ACCME.
Commercial Support Statements
This activity is supported by educational grants from Sanofi Genzyme and Regeneron Pharmaceuticals and Novartis Pharmaceutical Corporation.
Estimated time to complete the activity: 30 minutes
- During the period September 13, 2019 through September 13, 2020, participants must read the learning objectives and faculty disclosures and study the educational activity.
- If you wish to receive acknowledgment for completing this activity, please complete the post-test and evaluation following the activity. Upon successfully completing the post-test with a score of 80% or better and the activity evaluation, your certificate will be made available immediately.
There are no fees for participating and receiving CME credit for this activity.
©2019 MCM Education. All rights reserved. None of the contents may be reproduced in any form without prior written permission from the publisher. The opinions expressed in this educational activity are those of the faculty and do not necessarily reflect the opinions or recommendations of their affiliated institutions, the publisher, the University of Cincinnati, or Sanofi Genzyme and Regeneron Pharmaceuticals and Novartis Pharmaceutical Corporation. Any medications, diagnostic procedures, or treatments discussed by the program presenters should not be used by clinicians or other health care professionals without first evaluating their patients' conditions, considering possible contraindications or risks, reviewing any applicable manufacturer’s product information, and comparing any therapeutic approach with the recommendations of other authorities.